Ultralife Corporation
ULBI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.43 | -0.00 | 10.61 | 3.96 |
| FCF Yield | 11.92% | -0.56% | -4.73% | 1.56% |
| EV / EBITDA | 11.86 | 8.67 | 16.12 | 30.83 |
| Quality | ||||
| ROIC | 3.97% | 4.73% | 0.02% | 0.04% |
| Gross Margin | 25.73% | 24.71% | 22.30% | 25.08% |
| Cash Conversion Ratio | 2.60 | 0.27 | 10.53 | -18.80 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.65% | 17.31% | 6.97% | -2.74% |
| Free Cash Flow Growth | 2,460.19% | 78.82% | -294.71% | -91.88% |
| Safety | ||||
| Net Debt / EBITDA | 3.29 | 1.26 | 3.59 | 4.15 |
| Interest Coverage | 5.14 | 4.70 | 0.14 | 0.14 |
| Efficiency | ||||
| Inventory Turnover | 2.38 | 2.83 | 2.49 | 2.22 |
| Cash Conversion Cycle | 176.36 | 167.43 | 166.40 | 190.99 |